Lifu Pudding D7

Description

Rifabutin-d₇ is intended for use as an internal standard for the quantification of rifabutin by GC- or LC-MS. Rifabutin is a rifamycin antibiotic.^1,2 It is active against a variety of Gram-positive and Gram-negative bacteria, including 81 clinical isolates of H. pylori (MIC₅₀ = 0.25 μg/ml), as well as S. aureus, S. pyogenes, and C. trachomatis (MICs = 0.004, 0.005, and ~0.008 μg/ml, respectively). Rifabutin (0.5 μg/ml) is also active against 302 strains of M. tuberculosis.² It inhibits protein synthesis via inhibition of DNA-dependent RNA polymerase (RNAP) activity.² Rifabutin (10, 20, or 40 mg/kg) reduces the number of spleen, lung, and liver colony forming units (CFUs) in mouse models of disseminated Mycobacterium avium complex (MAC) infection.³ Formulations containing rifabutin have been used in the treatment of H. pylori infection.

The Uses of Lifu Pudding D7

Labelled Rifabutin (R505000). Semisynthetic derivative of Rifamycin S that inhibits nucleic acid synthesis. An antibacterial (tuberculostatic).

References

1. Heep, M., Beck, D., Bayerd?rffer, E., et al. Rifampin and rifabutin resistance mechanism in Helicobacter pylori Antimicrob. Agents Chemother. 43(6),1497-1499(1999).
2. Kunin, C.M. Antimicrobial activity of rifabutin Clin. Infect. Dis. 22(Supp. 1),S3-S14(1996).
3. Klemens, S.P., Grossi, M.A., and Cynamon, M.H. Comparative in vivo activities of rifabutin and rifapentine against Mycobacterium avium complex Antimicrob. Agents Chemother. 38(2),(1994).